West Pharmaceutical Services, Inc. has expanded the manufacturing capacity of its facility in Scottsdale, Arizona, to meet increased demand for its wearable injector device.
This expansion will enable continuing development and production of West’s SmartDose Electronic Wearable Injector.
The expanded capabilities at the Scottsdale site include clean room manufacturing and additional laboratory space. The company is creating new jobs in R&D, engineering, quality and operations functions to ramp-up production, new development and sustainment engineering.
“Expanding our manufacturing capabilities in Scottsdale — and continuing scaling up production in Israel — will enable rapid, dual sourcing to our customers and help them bring innovative new treatments to market,” commented Eric Resnick, president of Pharmaceutical Delivery Systems, Proprietary Products at West.
According to West, its electronic wearable injector injector is designed to deliver high volumes of injectable drugs over an extended period of time. The device makes it easier for patients to self-administer medication and encourages compliance with prescribed treatments.
The product has already been used by patients who have self-administered thousands of doses using SmartDose in clinical settings.
In addition, West has delivered more than 100,000 units of SmartDose and more than 800,000 validated Daikyo Crystal Zenith drug containers to pharmaceutical manufacturers for customer-funded development projects and clinical trials. Eight programs are currently at various stages of pre-commercial development.
